Intellectus Partners LLC Cuts Holdings in Zoetis Inc (NYSE:ZTS)

Intellectus Partners LLC cut its position in shares of Zoetis Inc (NYSE:ZTS) by 2.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,814 shares of the company’s stock after selling 226 shares during the quarter. Intellectus Partners LLC’s holdings in Zoetis were worth $973,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Huntington National Bank boosted its stake in Zoetis by 3.0% in the second quarter. Huntington National Bank now owns 2,975 shares of the company’s stock valued at $338,000 after acquiring an additional 87 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC boosted its stake in Zoetis by 1.8% in the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 4,980 shares of the company’s stock valued at $565,000 after acquiring an additional 89 shares during the last quarter. Vestmark Advisory Solutions Inc. boosted its stake in Zoetis by 0.6% in the second quarter. Vestmark Advisory Solutions Inc. now owns 15,106 shares of the company’s stock valued at $1,714,000 after acquiring an additional 89 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in Zoetis by 4.0% in the first quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock valued at $257,000 after acquiring an additional 97 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its stake in Zoetis by 0.7% in the second quarter. LS Investment Advisors LLC now owns 15,241 shares of the company’s stock valued at $1,730,000 after acquiring an additional 99 shares during the last quarter. Institutional investors and hedge funds own 90.09% of the company’s stock.

Zoetis stock traded up $1.77 during midday trading on Friday, reaching $129.18. 30,608 shares of the stock were exchanged, compared to its average volume of 1,941,813. The company’s fifty day moving average is $125.15 and its 200-day moving average is $112.84. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The firm has a market cap of $59.88 billion, a PE ratio of 41.26, a PEG ratio of 3.11 and a beta of 0.87. Zoetis Inc has a 52 week low of $78.90 and a 52 week high of $130.08.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. Zoetis’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.77 EPS. On average, sell-side analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $120.05, for a total transaction of $735,066.15. Following the completion of the transaction, the executive vice president now directly owns 41,698 shares of the company’s stock, valued at approximately $5,005,844.90. The disclosure for this sale can be found here. Insiders have sold a total of 34,332 shares of company stock worth $4,163,091 in the last ninety days. 0.29% of the stock is currently owned by insiders.

A number of research analysts have weighed in on the stock. Stifel Nicolaus set a $140.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, September 13th. Morgan Stanley boosted their target price on shares of Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research note on Monday, September 30th. Barclays boosted their price target on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Goldman Sachs Group started coverage on shares of Zoetis in a research report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price target on the stock. Finally, ValuEngine lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Zoetis has an average rating of “Buy” and an average price target of $123.19.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: How to use beta for portfolio diversification

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.